Decheng Capital Global Life Sciences Fund IV, L.P. - Jan 29, 2024 Form 4/A Insider Report for CG Oncology, Inc. (CGON)

Role: 10%+ Owner
Signature: Decheng Capital Global Life Sciences Fund IV, L.P., By Decheng Capital Management IV (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
Stock symbol: CGON
Transactions as of: Jan 29, 2024
Transactions value $: $7,600,000
Form type: 4/A
Date filed: 4/9/2024, 07:08 PM
Date Of Original Report: Jan 31, 2024
Previous filing: Jan 24, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CGON	Common Stock	Purchase	$7.6M	+400K	+8.77%	$19.00^*	4.96M	Jan 29, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Decheng Capital Global Life Sciences Fund IV, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Content

These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Remarks:

This Form 4 amendment is being filed to correct the original Form 4 filed on January 31, 2024, which inadvertently omitted the purchase of Common Stock reported herein.